Harvard Bioscience (HBIO) Non-Current Debt (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Debt data on file, last reported at $36.2 million in Q1 2026.

• Quarterly Non-Current Debt changed N/A year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (changed N/A YoY) and the FY2025 annual result came in at $35.9 million, changed N/A from the prior year.
• Non-Current Debt grew to $36.2 million in Q1 2026 per HBIO's latest filing, from $35.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $46.5 million in Q3 2022 and bottomed at $30.7 million in Q4 2023.
• The 5-year median for Non-Current Debt is $36.2 million (2026), against an average of $38.2 million.
• The widest annual swing landed in 2022, when Non-Current Debt climbed 11.83%; it then slipped 28.62% in 2023.
• Tracing HBIO's Non-Current Debt over 5 years: stood at $43.0 million in 2022, then fell by 28.62% to $30.7 million in 2023, then advanced by 11.56% to $34.3 million in 2024, then grew by 4.72% to $35.9 million in 2025, then grew by 0.95% to $36.2 million in 2026.
• Per Business Quant, the three latest HBIO Non-Current Debt figures stand at $36.2 million (Q1 2026), $35.9 million (Q4 2025), and $34.3 million (Q3 2024).

Peer Comparison